glp-1 agonist drugs oral New Guidelines for Type 2 Diabetes in 2025 glp 1 agonist oral or
Description
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
Gastrointestinal events are the most common: nausea, vomiting, diarrhoea, and constipation
Reduced appetite is the intended effect, though it sometimes feels too extreme
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
Ali MU, Mancini GBJ, Fitzpatrick-Lewis D, et al
These became widely available through telehealth companies at significantly lower prices
Once symptoms resolve, re-titration using a slower dose-escalation schedule may improve long-term tolerability
